Trade-offs between toxicity and progression-free survival in renal cell carcinoma therapies: a choice-format conjoint study of patient preferences

被引：0
|
作者：
Wong, M. K. [1 ]
Mohamed, A. F. [2 ]
Yang, J. C. [2 ]
Hauber, A. B. [3 ]
Liu, Z. [3 ]
Rogerio, J. [3 ]
Garay, C. A. [3 ]
机构：
[1] Univ So Calif, Los Angeles, CA 90089 USA
[2] RTI Hlth Solut, Res Triangle Pk, NC USA
[3] Nova Pharmaceut Corp, Basel, Switzerland
来源：
BJU INTERNATIONAL | 2012年 / 109卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
27
引用
收藏
页码：13 / 13
页数：1
相关论文
共 28 条
  • [1] Long progression-free survival with cabozantinib in a heavily pretreated patient with metastatic renal cell carcinoma: a case report
    Nasso, Cecilia
    Sabbatini, Roberto
    Baldessari, Cinzia
    Dominici, Massimo
    Vitale, Maria Giuseppa
    [J]. TUMORI JOURNAL, 2021, 107 (06): : NP33 - NP36
  • [2] Progression-free survival (PFS) and overall survival (OS) in patients receiving three targeted therapies (TTs) for metastatic renal cell carcinoma (mRCC)
    Verzoni, Elena
    Iacovelli, Roberto
    Rizzo, Mimma
    Felici, Alessandra
    Cascinu, Stefano
    Di Lorenzo, Giuseppe
    Cerbone, Linda
    Ortega, Cinzia
    Masini, Cristina
    Giganti, Maria Olga
    Lorusso, Vito
    Messina, Caterina
    Atzori, Francesco
    De Vincenzo, Fabio
    Sacco, Cosimo
    Boccardo, Francesco
    Valduga, Francesco
    Massari, Francesco
    Tassi, Renato
    Procopio, Giuseppe
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [3] External validation of nomograms for prediction of progression-free survival and liver toxicity in patients with advanced renal cell carcinoma treated with pazopanib
    Okamura, Yasuyoshi
    Hinata, Nobuyuki
    Terakawa, Tomoaki
    Furukawa, Junya
    Harada, Kenichi
    Nakano, Yuzo
    Nakamura, Ichiro
    Inoue, Takaaki
    Ogawa, Takayoshi
    Fujisawa, Masato
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2019, 24 (06) : 698 - 705
  • [4] Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma
    Flaherty, Keith T.
    Rosen, Mark A.
    Heitjan, Daniel F.
    Gallagher, Maryann L.
    Schwartz, Brian
    Schnall, Mitchell D.
    O'Dwyer, Peter J.
    [J]. CANCER BIOLOGY & THERAPY, 2008, 7 (04) : 496 - 501
  • [5] External validation of nomograms for prediction of progression-free survival and liver toxicity in patients with advanced renal cell carcinoma treated with pazopanib
    Yasuyoshi Okamura
    Nobuyuki Hinata
    Tomoaki Terakawa
    Junya Furukawa
    Kenichi Harada
    Yuzo Nakano
    Ichiro Nakamura
    Takaaki Inoue
    Takayoshi Ogawa
    Masato Fujisawa
    [J]. International Journal of Clinical Oncology, 2019, 24 : 698 - 705
  • [6] The correlation between the incidence of adverse events and progression-free survival in patients treated with cabozantinib for metastatic renal cell carcinoma (mRCC)
    Kucharz, Jakub
    Dumnicka, Paulina
    Kusnierz-Cabala, Beata
    Demkow, Tomasz
    Wiechno, Pawel
    [J]. MEDICAL ONCOLOGY, 2019, 36 (02)
  • [7] The correlation between the incidence of adverse events and progression-free survival in patients treated with cabozantinib for metastatic renal cell carcinoma (mRCC)
    Jakub Kucharz
    Paulina Dumnicka
    Beata Kusnierz-Cabala
    Tomasz Demkow
    Pawel Wiechno
    [J]. Medical Oncology, 2019, 36
  • [8] The association between renal sinus fat area and the progression-free survival in Chinese non-metastatic clear-cell renal cell carcinoma patients
    Huang, Haichao
    Chen, Shi
    Yu, Wei
    Ye, Zirong
    Li, Wei
    Xing, Jinchun
    Wu, Xiurong
    [J]. ONCOTARGET, 2017, 8 (39) : 65481 - 65491
  • [9] A Nomogram Including Sarcopenia for Predicting Progression-Free Survival in Patients with Localized Papillary Renal Cell Carcinoma: A Retrospective Cohort Study
    Su, Wenhui
    Wu, Yukun
    Liao, Shufen
    Zhang, Zhiqiang
    Zhang, Yubing
    Ou, Wei
    Yu, Jiajie
    Xiang, Fangzheng
    Luo, Cheng
    Zheng, Fufu
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (09) : 5815 - 5826
  • [10] Overall and progression-free survival with everolimus, temsirolimus, or sorafenib as second targeted therapies for metastatic renal cell carcinoma: A retrospective US chart review.
    Yang, Hongbo
    Wong, Michael K. K.
    Signorovitch, James E.
    Wang, Xufang
    Liu, Zhimei
    Liu, Nathan S.
    Qi, Zhengyun
    George, Daniel J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
123